Because the potential advantages of organoids over cancer cell cultures are increasingly recognised,9,10 we also generated patient-derived organoids and determined the dose-dependent effects of nivolumab by quantifying diameters, apoptosis, and PD-L1 expression, to establish the potential of this approach for the prediction of treatment responses. Here, CD274 is linked to cancer.